Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Xtant Medical Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Xtant Medical Holdings şirketinin toplam hissedar öz sermayesi $45.0M ve toplam borcu $33.7M olup, bu da borç-öz sermaye oranını 74.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $95.6M ve $50.6M dir.

Anahtar bilgiler

74.8%

Borç/özkaynak oranı

US$33.67m

Borç

Faiz karşılama oranı	n/a
Nakit	US$5.38m
Eşitlik	US$45.01m
Toplam yükümlülükler	US$50.57m
Toplam varlıklar	US$95.58m

Son finansal sağlık güncellemeleri

Recent updates

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

Mar 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: XTNT 'nin kısa vadeli varlıkları ( $69.0M ) kısa vadeli yükümlülüklerini ( $28.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: XTNT şirketinin kısa vadeli varlıkları ( $69.0M ) uzun vadeli yükümlülüklerini ( $22.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: XTNT 'nin net borç/öz sermaye oranı ( 62.9% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: XTNT şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: XTNT son raporlanan serbest nakit akışına göre 4 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: XTNT tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Xtant Medical Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards

Recent updates

Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus

Xtant Medical Holdings, Inc. announced that it has received $5 million in funding

New minor risk - Shareholder dilution

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024

New minor risk - Profitability

Price target increased by 27% to US$2.35

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023

Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Consensus EPS estimates fall by 17%, revenue upgraded

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus EPS estimates upgraded to US$0.06 loss

Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Announces Executive Changes

Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021)

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023

Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021)

Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022

Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding

Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021)

Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020)

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

New 90-day high: US$4.26

Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019)

Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding

Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: US$1.84

New 90-day high: US$1.52

Third quarter earnings released

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

New 90-day high: US$1.63

Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards

Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding

New 90-day low: US$0.76

New 90-day low - US$0.87

First half earnings released

Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020